The title of the article has been changed from “Oligodendrocytes: Potential of Discovering New Treatment Targets” to “Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
schizophrenia, mechanism of action, proteomics, biomarkers, chlorpromazine, haloperidol, quetiapine, risperidone
Citation
Brandão-Teles C, de Almeida V, Cassoli JS and Martins-de-Souza D (2019) Corrigendum: Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets. Front. Pharmacol. 10:344. doi: 10.3389/fphar.2019.00344
Received
18 March 2019
Accepted
19 March 2019
Published
09 April 2019
Approved by
Frontiers in Pharmacology Editorial Office, Frontiers Media SA, Switzerland
Volume
10 - 2019
Updates
Copyright
© 2019 Brandão-Teles, de Almeida, Cassoli and Martins-de-Souza.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daniel Martins-de-Souza dmsouza@unicamp.br; danms90@gmail.com
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.